This is a clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic and immunogenicity of single subcutaneous injection of SHR-4658 in healthy volunteers and volunteers with elevated blood pressure.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
48
SHR-4658 injection.
SHR-4658 placebo injection.
Beijing Anzhen Hospital Capital Medical University
Beijing, Beijing Municipality, China
Adverse events (AEs)
Time frame: Approximately 16 weeks.
Area under the concentration-time curve from time 0 to the last time point (AUC0-last)
Time frame: Approximately 16 weeks.
Area under the concentration-time curve from time 0 to infinity (AUC0-inf)
Time frame: Approximately 16 weeks.
Maximum observed concentration (Cmax)
Time frame: Approximately 16 weeks.
Time to maximum observed concentration (Tmax)
Time frame: Approximately 16 weeks.
Apparent clearance (CL/F)
Time frame: Approximately 16 weeks.
Apparent volume of distribution (Vd/F)
Time frame: Approximately 16 weeks.
Terminal elimination half-life (t1/2)
Time frame: Approximately 16 weeks.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.